Developer docs
API playgroundTry for free, no card

Search company profiles

Capitainer

Full company profile

uuid00026ld

Namestring
Capitainer
Legal namestring
Capitainer AB
Websiteurl
capitainer.se
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Capitainer is a Swedish medtech company developing volumetric microsampling devices that enable patients and laboratory personnel to collect precisely metered dried blood spot (DBS), plasma, and urine samples at home or in clinical settings without phlebotomy or cold-chain logistics. Founded in 2016 and headquartered in Solna, Sweden, the company commercializes its proprietary qDBS (quantitative Dried Blood Spot) microfluidic technology, which uses capillary channels to automatically meter fixed blood volumes (typically 10 µL) into pre-cut filter discs, eliminating the hematocrit-dependent volume bias that compromises conventional DBS sub-punch methods. The portfolio comprises five core hardware products—Capitainer B10 and B50 for whole blood, B10 Vanadate (which incorporates sodium metavanadate to inhibit post-sampling PEth formation) for alcohol-biomarker testing, SEP10 for capillary plasma microsampling without centrifugation, and DIP70 for urine microsampling—supplemented by lab-solution services, TSH testing, kitting support, and sampling-instruction packages.

The go-to-market combines direct digital sales through capitainer.com, enterprise sales to clinical laboratories, hospital systems, and public health agencies, and an emerging channel distribution network that includes Triolab for Sweden (June 2026) and consortium-led reach into Sub-Saharan Africa through the Karolinska Institutet-coordinated UTI-Diag project (11 partners across 7 countries). Pricing is not publicly disclosed; new customers complete request-pricing/sample flows and undergo credit assessment. The company's commercial validation is anchored in peer-reviewed publications across multiple high-impact journals (Eurosurveillance, Nature Communications, Nature Medicine, Scandinavian Journal of Clinical & Laboratory Investigation, Journal of Pharmaceutical and Biomedical Analysis) and includes named enterprise deployments at Region Västerbotten, the Public Health Agency of Sweden, Uppsala and Oslo University Hospitals, Sundsvall Hospital, Xerum AB, and First Wellness Testing, with documented outcomes such as a 500%+ increase in testing frequency in rural Västerbotten and >95% correct-sample arrival rates in the Swedish national COVID-19 antibody study.

Capitainer is privately held with a 11–50-employee headcount, a US subsidiary (Capitainer Inc) in East Providence, Rhode Island, and a leadership team led by CEO Christopher Aulin and CSO/Co-founder Olof Beck. Capital formation has totaled approximately $16M USD across multiple 2019–2024 tranches, with Sciety (a Swedish life-sciences investor) as the consistent lead investor across the 2020, 2022 and 2024 rounds and We Venture Capital joining as co-investor in early 2024.

Short descriptiontext

Capitainer AB is a Swedish medtech company developing volumetric microsampling devices for at-home, cold-chain-free collection of dried blood, plasma, and urine samples. It serves clinical laboratories, hospitals, public health agencies, and pharmaceutical research organizations across Europe, North America, and Africa.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
volumetric microsampling devices, dried blood spot technology, remote blood collection, microfluidic sampling devices, clinical diagnostics tools
Industry2 codes
PRIMARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Diagnostic Microsampling Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Microsampling Device Sales
TypeHardware Sales
Description

Capitainer generates revenue through the sale of its microsampling devices (Capitainer B10, B50, B10 Vanadate, SEP10, DIP70) and associated accessories and lab solutions, sold directly to healthcare providers, clinical laboratories, research institutions, and through distribution partners.

capitainer.com
2Laboratory Testing Services
TypeProfessional Services
Description

Capitainer offers laboratory testing services including TSH Testing, supporting diagnostic workflows where the company's sampling devices are used in combination with lab analysis services.

capitainer.com
3Kitting Support Services
TypeProfessional Services
Description

The company provides kitting support services and sampling instruction packages to help customers integrate Capitainer devices into their diagnostic or research workflows.

capitainer.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Capitainer develops and manufactures proprietary volumetric microsampling devices (qDBS technology) that enable patients to self-collect precise volumes of capillary blood, plasma, and urine at home via finger-prick. The microfluidic-based devices automatically meter exact sample volumes (e.g., 10 µL blood) into pre-cut filter discs with a built-in colorimetric success indicator, allowing quantitative dried blood spot analysis shipped at ambient temperature without cold chain logistics. The company also offers associated lab solutions, kitting support, sampling instruction packages, and TSH testing services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Testing frequency increased by over 500% in rural areas of Västerbotten when home sampling replaced traditional venous blood draws for COVID-19 serology
+7 more records
Product overview1 text field

Capitainer offers a portfolio of volumetric microsampling devices for collecting precise volumes of blood, plasma, and fluids. The core product line includes Capitainer®B10 and B50 for whole blood collection (10µL and 50µL respectively), Capitainer®SEP10 for plasma microsampling, Capitainer®B10 Vanadate for specialized PEth alcohol biomarker testing, and Capitainer®DIP70 for dried urine microsampling. All devices use proprietary microfluidic technology to automatically meter exact sample volumes to pre-cut filter discs, eliminating the hematocrit effect and enabling quantitative analysis. The portfolio also includes lab solutions, kitting support, and sampling instruction packages. The qDBS technology platform underlies all blood sampling products, providing consistent volumetric sampling with built-in success indicators.

Product and service1 record
1Capitainer®B10
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-24
Description

Capitainer entered a distribution partnership with Triolab for the Swedish market in June 2026. Triolab offers Capitainer's solutions for volumetric microsampling and self-sampling to laboratories and healthcare providers across Sweden. Triolab's experience in public procurement and established position within Swedish healthcare makes them a natural partner as more projects move toward clinical implementation of decentralized sampling solutions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Capitainer participates in the UTI-Diag international consortium coordinated by Karolinska Institutet, focused on improving diagnosis and management of urinary tract infections in Sub-Saharan Africa. The project brings together 11 partner organizations across 7 countries and is co-funded by the European Union through Global Health EDCTP3 and UK Research and Innovation. Capitainer contributes its DIP70 microsampling device for DNA-based detection of UTI pathogens.

3Institut Pasteur de Dakar
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Institut Pasteur de Dakar organized and hosted the International Conference on Diagnostic Innovation in Sub-Saharan Africa and the first annual UTI-Diag consortium meeting in June. The conference brought together researchers, healthcare professionals, industry representatives, and consortium partners from across Europe and Africa. Capitainer's R&D Manager participated in scientific exchange, workshops, and training activities.

capitainer.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Researchers from Umeå University collaborated with Karolinska Institute and Xerum AB to conduct a major retrospective cohort study demonstrating that home sampling with Capitainer qDBS devices greatly increased access to COVID-19 diagnostics in rural northern Sweden. The study was published in Eurosurveillance and is the first to demonstrate the impact of increased access to diagnostics with home sampling in a western country.

5Xerum AB
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Xerum AB collaborated on the Västerbotten COVID-19 serology surveillance study, serving as the clinical microbiology laboratory that analyzed qDBS samples alongside venous samples. Xerum CEO Julia Wigren Bystrom noted that large-scale serological testing was greatly simplified with Capitainer's DBS sampling, achieving near-100% successful sampling rates.

capitainer.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Researchers at Uppsala University's Department of Medical Science conducted a clinical evaluation of Capitainer B10 for at-home HbA1c sampling in diabetes patients. The study demonstrated excellent agreement between qDBS and venous blood samples on a Roche cobas 6000 analyzer, with results published in the Scandinavian Journal of Clinical & Laboratory Investigation.

7University Hospital Oslo / University of Oslo
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Norwegian researchers conducted a 6-month study in 2022 with 25 kidney transplant patients, comparing Capitainer B10 volumetric DBS microsampling with conventional venous blood sampling for routine monitoring of tacrolimus, creatinine, and hemoglobin. The study confirmed equal sampling success and analytical quality for self-sampling vs. healthcare-assisted sampling.

capitainer.com
Strategic tierMajorTypeTechnology or Integration
Description

Altasciences, a global contract research organization working with pharmaceutical companies in drug development, evaluated Capitainer qDBS for the quantification of 15 anti-epileptic drugs. The evaluation found that the device delivered accurate and precise blood volumes, was straightforward to use, and was devoid of the limitations of conventional DBS. Results were presented at AAPS PharmSci 360 2021.

9Diatropix
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Within the UTI-Diag project, consortium participants visited Diatropix's ISO 13485-certified manufacturing facility for rapid diagnostic tests, as part of the training and capacity-building activities organized during the conference in Dakar, Senegal.

capitainer.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Swedish research team from Karolinska Institute, Stockholm County Council, and ABC Labs developed and validated a multi-panel drug testing workflow combining Capitainer B10 qDBS with LC-MS/MS for detection of 35 analytes in clinical samples from a methadone maintenance clinic. The study demonstrated excellent agreement between qDBS and urine samples, with results published in Journal of Pharmaceutical and Biomedical Analysis.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Trajan-owned Neoteryx markets Mitra, a volumetric absorptive microsampling (VAMS) device for capillary blood collection. Mitra is a direct competitor to Capitainer's B10/B50 series in the same microsampling category, targeting clinical research and remote sampling workflows.

TypeDirect peer
Description

Tasso develops OnDemand and Tasso-Mini devices for patient-friendly capillary blood collection at home. It competes directly with Capitainer's qDBS in the decentralized clinical trials and remote patient monitoring markets.

3Spot On Sciences
TypeEmerging player
Description

Spot On Sciences makes HemaSpot and HemaSpot-PRO dried blood spot devices that compete with Capitainer's qDBS for ambient-temperature blood collection. While smaller in scale, it overlaps in the same DBS-for-remote-sampling use cases.

4Drawbridge Health
TypeEmerging player
Description

Drawbridge Health developed the OneDraw device for virtually painless self-collected blood samples. It addresses the same self-sampling-at-home thesis as Capitainer, with applications in chronic disease monitoring and decentralized trials.

TypeEmerging player
Description

Yourbio Health (formerly a Seventh Sense Biosystems spin-out) developed the TAP device for capillary blood collection at home. It is a comparable emerging microsampling player targeting the same home-based diagnostics and clinical trial use cases.

TypeEmerging player
Description

Babson Diagnostics is building a small-volume, capillary-based diagnostic testing service in partnership with Becton Dickinson. It addresses the same at-home/retail blood-collection thesis as Capitainer, though with a service-led model rather than a device-only offering.

TypeBroad incumbent
Description

PerkinElmer offers a broad portfolio of dried blood spot products and laboratory diagnostics services, including newborn screening and clinical research solutions. It is a larger incumbent with overlapping capabilities in DBS workflows and clinical diagnostics.

TypeBroad incumbent
Description

GE Healthcare's Whatman 903 Protein Saver Cards are the dominant legacy DBS card used in newborn screening and global health programs. As a broad incumbent, GE competes with Capitainer's qDBS in conventional DBS workflows and could expand into volumetric microsampling.

9Trajan Scientific and Medical
TypeBroad incumbent
Description

Trajan Scientific is a global analytical science company that owns Neoteryx and other microsampling assets. As the parent of Capitainer's closest direct competitor (Mitra), it represents the largest commercial-scale counterpart in the microsampling space.

TypeOthers
Description

Olink provides proteomics biomarker platforms that are compatible with Capitainer's qDBS samples (validated in partnership studies). Although not a direct competitor, it is an enabling ecosystem partner whose adoption of remote sampling amplifies Capitainer's TAM.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Capitainer

Diagnostic Microsampling Devicescapitainer.se

Capitainer AB is a Swedish medtech company developing volumetric microsampling devices for at-home, cold-chain-free collection of dried blood, plasma, and urine samples. It serves clinical laboratories, hospitals, public health agencies, and pharmaceutical research organizations across Europe, North America, and Africa.

What Capitainer does

Capitainer is a Swedish medtech company developing volumetric microsampling devices that enable patients and laboratory personnel to collect precisely metered dried blood spot (DBS), plasma, and urine samples at home or in clinical settings without phlebotomy or cold-chain logistics. Founded in 2016 and headquartered in Solna, Sweden, the company commercializes its proprietary qDBS (quantitative Dried Blood Spot) microfluidic technology, which uses capillary channels to automatically meter fixed blood volumes (typically 10 µL) into pre-cut filter discs, eliminating the hematocrit-dependent volume bias that compromises conventional DBS sub-punch methods. The portfolio comprises five core hardware products—Capitainer B10 and B50 for whole blood, B10 Vanadate (which incorporates sodium metavanadate to inhibit post-sampling PEth formation) for alcohol-biomarker testing, SEP10 for capillary plasma microsampling without centrifugation, and DIP70 for urine microsampling—supplemented by lab-solution services, TSH testing, kitting support, and sampling-instruction packages.

The go-to-market combines direct digital sales through capitainer.com, enterprise sales to clinical laboratories, hospital systems, and public health agencies, and an emerging channel distribution network that includes Triolab for Sweden (June 2026) and consortium-led reach into Sub-Saharan Africa through the Karolinska Institutet-coordinated UTI-Diag project (11 partners across 7 countries). Pricing is not publicly disclosed; new customers complete request-pricing/sample flows and undergo credit assessment. The company's commercial validation is anchored in peer-reviewed publications across multiple high-impact journals (Eurosurveillance, Nature Communications, Nature Medicine, Scandinavian Journal of Clinical & Laboratory Investigation, Journal of Pharmaceutical and Biomedical Analysis) and includes named enterprise deployments at Region Västerbotten, the Public Health Agency of Sweden, Uppsala and Oslo University Hospitals, Sundsvall Hospital, Xerum AB, and First Wellness Testing, with documented outcomes such as a 500%+ increase in testing frequency in rural Västerbotten and >95% correct-sample arrival rates in the Swedish national COVID-19 antibody study.

Capitainer is privately held with a 11–50-employee headcount, a US subsidiary (Capitainer Inc) in East Providence, Rhode Island, and a leadership team led by CEO Christopher Aulin and CSO/Co-founder Olof Beck. Capital formation has totaled approximately $16M USD across multiple 2019–2024 tranches, with Sciety (a Swedish life-sciences investor) as the consistent lead investor across the 2020, 2022 and 2024 rounds and We Venture Capital joining as co-investor in early 2024.

Capitainer firmographics

Firmographics
Name
Capitainer
Legal name
Capitainer AB
Website
https://capitainer.se
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Capitainer AB is a Swedish medtech company developing volumetric microsampling devices for at-home, cold-chain-free collection of dried blood, plasma, and urine samples. It serves clinical laboratories, hospitals, public health agencies, and pharmaceutical research organizations across Europe, North America, and Africa.
Ownership category
akta.pro rank

Capitainer industry classification

Industry
Product category
Diagnostic Microsampling Devices
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Volumetric microsampling devices
  • Dried blood spot technology
  • Remote blood collection
  • Microfluidic sampling devices
  • Clinical diagnostics tools

Where Capitainer is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Capitainer business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Microsampling Device Sales: Capitainer generates revenue through the sale of its microsampling devices (Capitainer B10, B50, B10 Vanadate, SEP10, DIP70) and associated accessories and lab solutions, sold directly to healthcare providers, clinical laboratories, research institutions, and through distribution partners.
  2. Laboratory Testing Services: Capitainer offers laboratory testing services including TSH Testing, supporting diagnostic workflows where the company's sampling devices are used in combination with lab analysis services.
  3. Kitting Support Services: The company provides kitting support services and sampling instruction packages to help customers integrate Capitainer devices into their diagnostic or research workflows.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Capitainer product offering

Product offering

Core offering

Capitainer develops and manufactures proprietary volumetric microsampling devices (qDBS technology) that enable patients to self-collect precise volumes of capillary blood, plasma, and urine at home via finger-prick. The microfluidic-based devices automatically meter exact sample volumes (e.g., 10 µL blood) into pre-cut filter discs with a built-in colorimetric success indicator, allowing quantitative dried blood spot analysis shipped at ambient temperature without cold chain logistics. The company also offers associated lab solutions, kitting support, sampling instruction packages, and TSH testing services.

Product overview

Capitainer offers a portfolio of volumetric microsampling devices for collecting precise volumes of blood, plasma, and fluids. The core product line includes Capitainer®B10 and B50 for whole blood collection (10µL and 50µL respectively), Capitainer®SEP10 for plasma microsampling, Capitainer®B10 Vanadate for specialized PEth alcohol biomarker testing, and Capitainer®DIP70 for dried urine microsampling. All devices use proprietary microfluidic technology to automatically meter exact sample volumes to pre-cut filter discs, eliminating the hematocrit effect and enabling quantitative analysis. The portfolio also includes lab solutions, kitting support, and sampling instruction packages. The qDBS technology platform underlies all blood sampling products, providing consistent volumetric sampling with built-in success indicators.

Differentiator

Problem solved

Functional benefit

Products and services

  • Capitainer®B10

Quantifiable outcome

  • Testing frequency increased by over 500% in rural areas of Västerbotten when home sampling replaced traditional venous blood draws for COVID-19 serology
  • +7 more outcomes

Companies that use Capitainer

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Capitainer technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Capitainer partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, major and minor.

  • TriolabcoreChannel Partner/ Reseller/ Distributor · 24 June 2026Capitainer entered a distribution partnership with Triolab for the Swedish market in June 2026. Triolab offers Capitainer's solutions for volumetric microsampling and self-sampling to laboratories and healthcare providers across Sweden. Triolab's experience in public procurement and established position within Swedish healthcare makes them a natural partner as more projects move toward clinical implementation of decentralized sampling solutions.
  • Karolinska Institutet (UTI-Diag Consortium)coreStrategic or Co-development PartnerCapitainer participates in the UTI-Diag international consortium coordinated by Karolinska Institutet, focused on improving diagnosis and management of urinary tract infections in Sub-Saharan Africa. The project brings together 11 partner organizations across 7 countries and is co-funded by the European Union through Global Health EDCTP3 and UK Research and Innovation. Capitainer contributes its DIP70 microsampling device for DNA-based detection of UTI pathogens.
  • Institut Pasteur de DakarcoreStrategic or Co-development PartnerInstitut Pasteur de Dakar organized and hosted the International Conference on Diagnostic Innovation in Sub-Saharan Africa and the first annual UTI-Diag consortium meeting in June. The conference brought together researchers, healthcare professionals, industry representatives, and consortium partners from across Europe and Africa. Capitainer's R&D Manager participated in scientific exchange, workshops, and training activities.
  • Umeå UniversitymajorStrategic or Co-development PartnerResearchers from Umeå University collaborated with Karolinska Institute and Xerum AB to conduct a major retrospective cohort study demonstrating that home sampling with Capitainer qDBS devices greatly increased access to COVID-19 diagnostics in rural northern Sweden. The study was published in Eurosurveillance and is the first to demonstrate the impact of increased access to diagnostics with home sampling in a western country.
  • Xerum ABmajorStrategic or Co-development PartnerXerum AB collaborated on the Västerbotten COVID-19 serology surveillance study, serving as the clinical microbiology laboratory that analyzed qDBS samples alongside venous samples. Xerum CEO Julia Wigren Bystrom noted that large-scale serological testing was greatly simplified with Capitainer's DBS sampling, achieving near-100% successful sampling rates.
  • Uppsala University HospitalmajorStrategic or Co-development PartnerResearchers at Uppsala University's Department of Medical Science conducted a clinical evaluation of Capitainer B10 for at-home HbA1c sampling in diabetes patients. The study demonstrated excellent agreement between qDBS and venous blood samples on a Roche cobas 6000 analyzer, with results published in the Scandinavian Journal of Clinical & Laboratory Investigation.
  • University Hospital Oslo / University of OslomajorStrategic or Co-development PartnerNorwegian researchers conducted a 6-month study in 2022 with 25 kidney transplant patients, comparing Capitainer B10 volumetric DBS microsampling with conventional venous blood sampling for routine monitoring of tacrolimus, creatinine, and hemoglobin. The study confirmed equal sampling success and analytical quality for self-sampling vs. healthcare-assisted sampling.
  • AltasciencesmajorTechnology or IntegrationAltasciences, a global contract research organization working with pharmaceutical companies in drug development, evaluated Capitainer qDBS for the quantification of 15 anti-epileptic drugs. The evaluation found that the device delivered accurate and precise blood volumes, was straightforward to use, and was devoid of the limitations of conventional DBS. Results were presented at AAPS PharmSci 360 2021.
  • DiatropixminorStrategic or Co-development PartnerWithin the UTI-Diag project, consortium participants visited Diatropix's ISO 13485-certified manufacturing facility for rapid diagnostic tests, as part of the training and capacity-building activities organized during the conference in Dakar, Senegal.
  • Karolinska Institute, Stockholm County Council, ABC Labs (Sweden)majorStrategic or Co-development PartnerSwedish research team from Karolinska Institute, Stockholm County Council, and ABC Labs developed and validated a multi-panel drug testing workflow combining Capitainer B10 qDBS with LC-MS/MS for detection of 35 analytes in clinical samples from a methadone maintenance clinic. The study demonstrated excellent agreement between qDBS and urine samples, with results published in Journal of Pharmaceutical and Biomedical Analysis.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Capitainer competitors and assessment

Company assessment

Direct peers

  • Neoteryx (Trajan Scientific): Trajan-owned Neoteryx markets Mitra, a volumetric absorptive microsampling (VAMS) device for capillary blood collection. Mitra is a direct competitor to Capitainer's B10/B50 series in the same microsampling category, targeting clinical research and remote sampling workflows.
  • Tasso: Tasso develops OnDemand and Tasso-Mini devices for patient-friendly capillary blood collection at home. It competes directly with Capitainer's qDBS in the decentralized clinical trials and remote patient monitoring markets.

Emerging players

  • Spot On Sciences: Spot On Sciences makes HemaSpot and HemaSpot-PRO dried blood spot devices that compete with Capitainer's qDBS for ambient-temperature blood collection. While smaller in scale, it overlaps in the same DBS-for-remote-sampling use cases.
  • Drawbridge Health: Drawbridge Health developed the OneDraw device for virtually painless self-collected blood samples. It addresses the same self-sampling-at-home thesis as Capitainer, with applications in chronic disease monitoring and decentralized trials.
  • Yourbio Health: Yourbio Health (formerly a Seventh Sense Biosystems spin-out) developed the TAP device for capillary blood collection at home. It is a comparable emerging microsampling player targeting the same home-based diagnostics and clinical trial use cases.
  • Babson Diagnostics: Babson Diagnostics is building a small-volume, capillary-based diagnostic testing service in partnership with Becton Dickinson. It addresses the same at-home/retail blood-collection thesis as Capitainer, though with a service-led model rather than a device-only offering.

Broad incumbents

  • PerkinElmer: PerkinElmer offers a broad portfolio of dried blood spot products and laboratory diagnostics services, including newborn screening and clinical research solutions. It is a larger incumbent with overlapping capabilities in DBS workflows and clinical diagnostics.
  • GE Healthcare (Cytiva / Whatman): GE Healthcare's Whatman 903 Protein Saver Cards are the dominant legacy DBS card used in newborn screening and global health programs. As a broad incumbent, GE competes with Capitainer's qDBS in conventional DBS workflows and could expand into volumetric microsampling.
  • Trajan Scientific and Medical: Trajan Scientific is a global analytical science company that owns Neoteryx and other microsampling assets. As the parent of Capitainer's closest direct competitor (Mitra), it represents the largest commercial-scale counterpart in the microsampling space.

Others

  • Olink Holding: Olink provides proteomics biomarker platforms that are compatible with Capitainer's qDBS samples (validated in partnership studies). Although not a direct competitor, it is an enabling ecosystem partner whose adoption of remote sampling amplifies Capitainer's TAM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Capitainer social profiles

Digital presence

Capitainer financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Capitainer leadership team

Management profile

Number of profiles

Profiles6 records

Capitainer funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Capitainer M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Capitainer

What does Capitainer do?

Capitainer develops and manufactures proprietary volumetric microsampling devices (qDBS technology) that enable patients to self-collect precise volumes of capillary blood, plasma, and urine at home via finger-prick. The microfluidic-based devices automatically meter exact sample volumes (e.g., 10 µL blood) into pre-cut filter discs with a built-in colorimetric success indicator, allowing quantitative dried blood spot analysis shipped at ambient temperature without cold chain logistics. The company also offers associated lab solutions, kitting support, sampling instruction packages, and TSH testing services.

Is Capitainer a public or private company?

Capitainer is a private company. It is classified as venture growth investor backed and is currently operating.

When was Capitainer founded?

Capitainer was founded in 2016. It employs 11 to 50 people.

Where is Capitainer based?

Capitainer is headquartered in Solna, Sweden, in the Europe region.

How does Capitainer make money?

Three revenue lines are on record. Microsampling Device Sales are the primary driver. The others are laboratory Testing Services and kitting Support Services.

Who are Capitainer's main competitors?

Direct peers on record are Neoteryx (Trajan Scientific) and Tasso. Emerging players are Spot On Sciences, Drawbridge Health, Yourbio Health and Babson Diagnostics. Broad incumbents are PerkinElmer, GE Healthcare (Cytiva / Whatman) and Trajan Scientific and Medical. Olink Holding is listed as an others.

Does Capitainer have an API?

No public API is recorded for Capitainer.

What industry is Capitainer in?

Capitainer's product category is Diagnostic Microsampling Devices. Its primary akta.pro industry code is HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TrendHunter.comMail-In Blood Test CardsCapitainer advanced its HbA1c program to clinical stage, with the first sample collected in a U.S. study centered on its Capitainer B50 microsampling card. The study, expected to enroll at least 120 participants, supports a planned FDA 510(k) filing for HbA1c testing. Data collection is slated to wrap in November 2026.AktienCapitainer Initiates Clinical Sampling for HbA1c FDA 510(k) StudyCapitainer collected the first clinical sample for its HbA1c study, supporting a planned FDA 510(k) submission. The study will include at least 120 participants and compare self-sampling results to conventional venous samples, with data collection expected to complete in November 2026.PR NewswireCapitainer Initiates Clinical Sampling for HbA1c FDA 510(k) StudyCapitainer collected the first clinical sample for its HbA1c FDA 510(k) study, which will include at least 120 participants. The study compares self-sampling and assisted capillary blood collection using Capitainer B50 against conventional venous samples, with data collection expected to complete in November 2026.PR NewswireCapitainer Initiates Clinical Sampling for HbA1c FDA 510(k) StudyCapitainer collected the first clinical sample for its HbA1c FDA 510(k) study, which will include at least 120 participants. The study compares self-sampling and assisted capillary blood collection using Capitainer B50 against conventional venous samples, with data collection expected to complete in November 2026.news.cision.comCapitainer Initiates Clinical Sampling for HbA1c FDA 510(k) StudyCapitainer collected the first clinical sample for its HbA1c FDA 510(k) study, which will include at least 120 participants. The study compares self-sampling and assisted capillary blood collection using Capitainer B50 against conventional venous samples, with data collection expected to complete in November 2026.PR NewswireNew Publication Further Validates Capitainer Technology for Remote Alzheimer's Disease Biomarker TestingA new publication in Nature Communications demonstrates that remotely self-collected capillary blood samples using Capitainer's volumetric microsampling cards can reliably measure Alzheimer's disease biomarkers associated with cognitive decline in older adults. The study found strong correlations between capillary and venous blood biomarkers while enabling participants to collect samples at home and return them by post. Capitainer AB's CEO stated that these publications represent an important step toward making Alzheimer's disease biomarker testing more accessible and scalable beyond traditional clinical settings.news.cision.comNew Publication Further Validates Capitainer Technology for Remote Alzheimer’s Disease Biomarker TestingA new Nature Communications study shows that remotely self-collected capillary blood samples can measure Alzheimer's disease biomarkers linked to cognitive decline in older adults. The findings build on the DROP-AD study and demonstrate strong correlations between capillary and venous blood biomarkers. The results support broader, scalable testing beyond traditional clinical settings.Longevity.TechnologyNew Alzheimer therapies trigger diagnostic shakeupRe:Cognition Health launched CognitionCheck, a £1,295 multi-modal screening pathway combining MRI, AI testing, and p-Tau217 blood biomarkers. A Nature Communications study validated remote capillary blood sampling for Alzheimer's biomarkers, enabling decentralized testing. The convergence signals a shift toward low-cost, ambient monitoring for population-scale screening.news.cision.comCapitainer launches DIP70 – a new device for dried urine microsamplingCapitainer, a Swedish MedTech company, announced the launch of Capitainer®DIP70, a volumetric dried urine microsampling device that automatically collects two precisely metered 70 µL samples for remote use. The device enables convenient and hygienic urine sampling at home or in clinical settings, with the dried format allowing shipment via regular mail without cold chain logistics while minimizing microbial growth and analyte degradation risks. The launch expands Capitainer's self-sampling portfolio beyond blood and plasma, positioning the company to offer a complete solution for decentralized sampling across clinical, research, and toxicology applications.